PL3674318T3 - Zoptymalizowane warianty Fc - Google Patents

Zoptymalizowane warianty Fc

Info

Publication number
PL3674318T3
PL3674318T3 PL20151751.3T PL20151751T PL3674318T3 PL 3674318 T3 PL3674318 T3 PL 3674318T3 PL 20151751 T PL20151751 T PL 20151751T PL 3674318 T3 PL3674318 T3 PL 3674318T3
Authority
PL
Poland
Prior art keywords
variants
optimized
Prior art date
Application number
PL20151751.3T
Other languages
English (en)
Inventor
Christian Behrens
Sylvie Jorieux
Abdelhakim Kharrat
Khalil Bouayadi
Philippe Mondon
Céline Monnet-Mars
Original Assignee
Laboratoire Français Du Fractionnement Et Des Biotechnologies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoire Français Du Fractionnement Et Des Biotechnologies filed Critical Laboratoire Français Du Fractionnement Et Des Biotechnologies
Publication of PL3674318T3 publication Critical patent/PL3674318T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL20151751.3T 2009-03-20 2010-03-19 Zoptymalizowane warianty Fc PL3674318T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09305250A EP2233500A1 (en) 2009-03-20 2009-03-20 Optimized Fc variants

Publications (1)

Publication Number Publication Date
PL3674318T3 true PL3674318T3 (pl) 2025-03-24

Family

ID=40578514

Family Applications (2)

Application Number Title Priority Date Filing Date
PL14163605T PL2805969T4 (pl) 2009-03-20 2010-03-19 Zoptymalizowane warianty FC
PL20151751.3T PL3674318T3 (pl) 2009-03-20 2010-03-19 Zoptymalizowane warianty Fc

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL14163605T PL2805969T4 (pl) 2009-03-20 2010-03-19 Zoptymalizowane warianty FC

Country Status (14)

Country Link
US (3) US8742074B2 (pl)
EP (6) EP2233500A1 (pl)
JP (2) JP5770710B2 (pl)
KR (3) KR101781318B1 (pl)
CN (2) CN104892762A (pl)
AU (1) AU2010224800B2 (pl)
BR (2) BRPI1014525B1 (pl)
CA (3) CA2995516C (pl)
DK (2) DK2805969T3 (pl)
ES (2) ES2726625T3 (pl)
IL (2) IL215041A (pl)
PL (2) PL2805969T4 (pl)
TR (1) TR201904385T4 (pl)
WO (1) WO2010106180A2 (pl)

Families Citing this family (181)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
EP2009101B1 (en) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
EP3415529B1 (en) 2007-09-26 2020-11-04 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
EP2275443B1 (en) 2008-04-11 2015-12-02 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
TWI682995B (zh) 2009-03-19 2020-01-21 日商中外製藥股份有限公司 抗體恆定區域改變體
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US10435458B2 (en) 2010-03-04 2019-10-08 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variants with reduced Fcgammar binding
JP2013528357A (ja) 2010-03-29 2013-07-11 ザイムワークス，インコーポレイテッド 強化又は抑制されたエフェクター機能を有する抗体
WO2011124635A1 (en) 2010-04-07 2011-10-13 Humalys Binding molecules against chikungunya virus and uses thereof
RU2604811C2 (ru) 2010-05-27 2016-12-10 Мерк Шарп Энд Домэ Корп. Способ получения антител с улучшенными свойствами
CA2806252C (en) 2010-07-29 2019-05-14 Xencor, Inc. Antibodies with modified isoelectric points
KR101962483B1 (ko) 2010-11-17 2019-03-29 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
TWI654204B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
WO2012132067A1 (ja) * 2011-03-30 2012-10-04 中外製薬株式会社 抗原結合分子の血漿中滞留性と免疫原性を改変する方法
CA2827923C (en) 2011-02-25 2021-11-23 Chugai Seiyaku Kabushiki Kaisha Fc.gamma.riib-specific fc antibody
US9346883B2 (en) 2011-05-13 2016-05-24 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antibodies against HER3
JP2014517846A (ja) 2011-05-25 2014-07-24 メルク・シャープ・アンド・ドーム・コーポレーション 改善された特性を有するＦｃ含有ポリペプチドの製造方法
JP6033293B2 (ja) 2011-06-22 2016-11-30 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル）Ｉｎｓｅｒｍ（Ｉｎｓｔｉｔｕｔ Ｎａｔｉｏｎａｌ Ｄｅｌａ Ｓａｎｔｅ Ｅｔ Ｄｅ Ｌａ Ｒｅｃｈｅｒｃｈｅ Ｍｅｄｉｃａｌｅ） 抗Ａｘｌ抗体及びその使用
US9409988B2 (en) 2011-06-22 2016-08-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-Axl antibodies and uses thereof
EP2537864B1 (en) * 2011-06-24 2019-08-07 Laboratoire Français du Fractionnement et des Biotechnologies Fc variants with reduced effector functions
JP5997151B2 (ja) 2011-06-30 2016-09-28 中外製薬株式会社 ヘテロ二量化ポリペプチド
KR20200120743A (ko) * 2011-07-06 2020-10-21 젠맵 비. 브이 항체 변이체 및 그의 용도
UA117901C2 (uk) * 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
TW201817744A (zh) * 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
BR112014007484A2 (pt) 2011-09-30 2017-04-04 Chugai Pharmaceutical Co Ltd molécula de ligação a antígeno de indução de resposta imune a antígeno alvo
WO2013047752A1 (ja) 2011-09-30 2013-04-04 中外製薬株式会社 抗原の消失を促進する抗原結合分子
US20150050269A1 (en) * 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
CA3182462A1 (en) * 2011-10-10 2013-04-18 Xencor, Inc. A method for purifying antibodies
US10851178B2 (en) * 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US12466897B2 (en) * 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
ES2732712T3 (es) 2011-10-31 2019-11-25 Chugai Pharmaceutical Co Ltd Molécula de unión a antígeno que tiene una conjugación regulada entre la cadena pesada y la cadena ligera
EP2780463A4 (en) * 2011-11-18 2015-07-01 Merck Sharp & Dohme FC-CONTAINING POLYPEPTIDES WITH INCREASED INFLAMMATORY FEATURES AND INCREASED FCRN BINDING
CA3233142A1 (en) 2011-11-30 2013-06-06 Chugai Seiyaku Kabushiki Kaisha Drug containing carrier into cell for forming immune complex
KR102041412B1 (ko) * 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
EP2813568B1 (en) 2012-02-09 2025-04-23 Chugai Seiyaku Kabushiki Kaisha Modified fc region of antibody
WO2013125667A1 (ja) 2012-02-24 2013-08-29 中外製薬株式会社 FcγRIIBを介して抗原の消失を促進する抗原結合分子
SG10202006507XA (en) 2012-05-30 2020-08-28 Chugai Pharmaceutical Co Ltd Target-tissue-specific antigen-binding molecule
DK2869845T3 (da) * 2012-07-06 2019-12-09 Genmab Bv Dimert protein med tredobbelte mutationer
EP3632462A1 (en) * 2012-07-06 2020-04-08 Genmab B.V. Dimeric protein with triple mutations
US11180572B2 (en) * 2012-07-06 2021-11-23 Genmab B.V. Dimeric protein with triple mutations
SG11201500873XA (en) 2012-08-24 2015-04-29 Chugai Pharmaceutical Co Ltd Fcgriib-specific fc region variant
TWI613212B (zh) * 2012-10-02 2018-02-01 波克萊拉生物科技股份有限公司 作爲澱粉樣蛋白結合劑之ｇ３ｐ融合蛋白
EP2733153A1 (en) 2012-11-15 2014-05-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the preparation of immunoconjugates and uses thereof
AU2013372331A1 (en) * 2013-01-10 2015-07-23 Genmab B.V. Human IgG1 Fc region variants and uses thereof
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
CA2898100C (en) 2013-01-14 2023-10-10 Xencor, Inc. Novel heterodimeric proteins
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
CA2897987A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
GB201302878D0 (en) * 2013-02-19 2013-04-03 Argen X Bv Modified igG molecules
EP2970486B1 (en) 2013-03-15 2018-05-16 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
TWI636062B (zh) 2013-04-02 2018-09-21 中外製藥股份有限公司 Fc region variant
RU2655439C2 (ru) 2013-05-31 2018-05-28 Займворкс Инк. Гетеромультимеры с уменьшенной или подавленной эффекторной функцией
KR101895634B1 (ko) * 2013-05-31 2018-09-05 한미약품 주식회사 변이된 힌지 영역을 포함하는 IgG4 Fc 단편
KR102116495B1 (ko) * 2013-08-28 2020-06-03 삼성디스플레이 주식회사 축합환 화합물을 포함하는 유기 전계 발광 소자
CA2923145C (en) * 2013-09-05 2025-09-16 Amgen Inc. MOLECULES CONTAINING FCS AND EXHIBITING PREDICTABLE, UNIFORM AND REPRODUCIBLE GLYCOFORM PROFILES
CN105764922B (zh) 2013-09-27 2020-07-17 中外制药株式会社 多肽异源多聚体的制备方法
WO2015054039A1 (en) * 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Fc CONTAINING POLYPEPTIDES HAVING INCREASED BINDING TO FcGammaRIIB
FR3012453B1 (fr) 2013-10-31 2015-11-13 Lab Francais Du Fractionnement Proteine chimerique dans le traitement de l’amylose
CA2929386C (en) 2013-11-07 2023-01-03 Inserm (Institut National De La Sante Et De La Recherche Medicale) Neuregulin allosteric anti-her3 antibody
WO2015073307A2 (en) * 2013-11-13 2015-05-21 Merck Sharp & Dohme Corp. Fc CONTAINING POLYPEPTIDES HAVING INCREASED BINDING TO HUMAN DC-SIGN
CA2934644C (en) * 2013-12-24 2023-11-21 Argen-X N.V. Fcrn antagonists and methods of use
US10421796B2 (en) * 2014-01-21 2019-09-24 Gray D Shaw Variants of IgG Fc with limited amine groups
JP6775422B2 (ja) 2014-03-28 2020-10-28 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ３８及びｃｄ３に結合する二重特異性抗体
CA2946430A1 (en) * 2014-06-12 2015-12-17 F. Hoffmann-La Roche Ag Method for selecting antibodies with modified fcrn interaction
FR3024453B1 (fr) 2014-08-01 2018-06-29 Lab Francais Du Fractionnement Procede de production de variants ayant un fc presentant une sialylation amelioree
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
JP2017536830A (ja) 2014-11-26 2017-12-14 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ３及びｃｄ３８に結合するヘテロ二量体抗体
SG11201704283PA (en) 2014-11-26 2017-06-29 Xencor Inc Heterodimeric antibodies that bind cd3 and tumor antigens
EP3229836B1 (en) 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Human monoclonal antibodies against axl
NZ730607A (en) 2014-12-19 2022-07-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
WO2016125495A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
FR3034420A1 (fr) 2015-03-31 2016-10-07 Lab Francais Du Fractionnement Anticorps monoclonaux anti-cd303
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
FR3035879B1 (fr) * 2015-05-07 2025-02-28 Lab Francais Du Fractionnement Mutants fc a activite fonctionnelle modifiee
WO2016188911A1 (en) 2015-05-22 2016-12-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies fragments inhibiting both the cath-d catalytic activity and its binding to the lrp1 receptor
FR3038517B1 (fr) * 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
FR3039832A1 (fr) * 2015-08-04 2017-02-10 Univ Francois Rabelais De Tours Igg1 et leur utilisation therapeutique
JP7058219B2 (ja) 2015-12-07 2022-04-21 ゼンコア インコーポレイテッド Ｃｄ３及びｐｓｍａに結合するヘテロ二量体抗体
EP3390443A4 (en) 2015-12-18 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES WITH DEVIANT FC REGIONS AND METHOD OF USE
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
CA3016424A1 (en) 2016-03-14 2017-09-21 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
WO2017162678A1 (en) 2016-03-22 2017-09-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Humanized anti-claudin-1 antibodies and uses thereof
ES3055961T3 (en) 2016-04-28 2026-02-17 Chugai Pharmaceutical Co Ltd Antibody-containing preparation
FR3051794A1 (fr) * 2016-05-31 2017-12-01 Lab Francais Du Fractionnement Anticorps pour le traitement de cancers
MA45255A (fr) 2016-06-14 2019-04-17 Xencor Inc Anticorps inhibiteurs de points de contrôle bispécifiques
MX2018014375A (es) 2016-06-17 2019-04-22 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina y metodos de uso.
KR20190020341A (ko) 2016-06-28 2019-02-28 젠코어 인코포레이티드 소마토스타틴 수용체 2에 결합하는 이종이량체 항체
FR3053688B1 (fr) * 2016-07-06 2026-05-01 Lab Francais Du Fractionnement Mutants fc a activite fonctionnelle amelioree
EP3481864A1 (en) 2016-07-08 2019-05-15 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
US11186634B2 (en) 2016-07-29 2021-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies targeting tumor associated macrophages and uses thereof
FI3494134T3 (fi) 2016-08-02 2026-02-19 Visterra Inc Muunneltuja polypeptidejä ja niiden käyttötapoja
BR112019001902A2 (pt) 2016-08-05 2019-07-09 Chugai Seiyaku Kabushiki Kaisha composição para profilaxia ou tratamento de doenças relacionadas à il-8
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
BR112019007281A2 (pt) 2016-10-14 2019-07-09 Xencor Inc proteína heterodimérica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica e para tratar câncer em um paciente
WO2018085400A1 (en) 2016-11-02 2018-05-11 Vanderbilt University Human zika virus antibodies and methods of use therefor
KR101872455B1 (ko) * 2016-11-30 2018-06-28 국민대학교 산학협력단 신규한 돌연변이를 포함하는 항체 Ｆｃ 영역
NZ756763A (en) 2017-02-17 2023-04-28 Denali Therapeutics Inc Engineered transferrin receptor binding polypeptides
EP3589654A1 (en) 2017-03-02 2020-01-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof
FR3064007A1 (fr) 2017-03-20 2018-09-21 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Anticorps pour le traitement de cancers
EP3603670A4 (en) 2017-03-31 2021-03-10 Public University Corporation Nara Medical University MEDICAL COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF BLOOD CLOG FACTOR IX ANOMALY WITH A MULTI-SPECIFIC ANTIGIBINDING MOLECULAR FUNCTION OF BLOOD CLOTHING FACTOR VIII
KR101913743B1 (ko) * 2017-04-07 2018-11-01 국민대학교 산학협력단 혈중 반감기 연장을 위한 항체 Fc 변이체들
KR101792205B1 (ko) 2017-04-13 2017-10-31 재단법인 오송첨단의료산업진흥재단 혈중 지속성 연장을 위한 항체 Fc 변이체들
WO2018186717A1 (ko) * 2017-04-07 2018-10-11 국민대학교 산학협력단 혈중 반감기 향상을 위한 항체 Fc 변이체들
CA3059133A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
AU2018291497A1 (en) 2017-06-30 2020-01-16 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
EP3456737B1 (en) 2017-09-19 2024-02-14 Tillotts Pharma Ag Antibody variants
SMT202100313T1 (it) 2017-09-19 2021-07-12 Tillotts Pharma Ag Composti 1-ciano-pirrolidinici come inibitori di usp30
AU2018350990A1 (en) * 2017-10-18 2020-05-21 Regenxbio Inc. Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified VEGF-Trap
CA3080103A1 (en) 2017-10-31 2019-05-09 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
TW202600611A (zh) 2017-11-01 2026-01-01 日商中外製藥股份有限公司 生物活性降低之抗體變異體與同功型
AU2018366199A1 (en) 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
MX2020005981A (es) 2017-12-08 2020-08-24 Argenx Bvba Uso de antagonistas del fcrn para el tratamiento de la miastenia gravis generalizada.
EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
FR3075200B1 (fr) * 2017-12-15 2022-12-23 Lab Francais Du Fractionnement Variants avec fragment fc ayant une affinite augmentee pour fcrn et une affinite augmentee pour au moins un recepteur du fragment fc
AU2018390418B2 (en) 2017-12-19 2023-12-21 Xencor, Inc. Engineered IL-2 Fc fusion proteins
FR3076294B1 (fr) 2017-12-29 2022-01-28 Lab Francais Du Fractionnement Procede de purification d'anticorps a partir de lait brut
CN108101992B (zh) * 2017-12-31 2021-03-26 武汉班科生物技术股份有限公司 与新生的Fc受体结合增强的CH2结构域突变体及其制备方法与应用
MA51666A (fr) * 2018-01-24 2020-12-02 Genmab Bv Variants polypeptidiques et leurs utilisations
JP2018138022A (ja) * 2018-02-23 2018-09-06 ゲンマブ ビー．ブイ． ヒトＩｇＧ１ Ｆｃ領域変異体およびその使用
CA3093729A1 (en) 2018-03-15 2019-09-19 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
AU2019247415A1 (en) 2018-04-04 2020-10-22 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
JP7516254B2 (ja) 2018-04-18 2024-07-16 ゼンコア インコーポレイテッド Ｉｌ－１５／ｉｌ－１５ｒａヘテロ二量体ｆｃ融合タンパク質およびその使用
JP2021520829A (ja) 2018-04-18 2021-08-26 ゼンコア インコーポレイテッド ＩＬ−１５／ＩＬ−１５ＲＡ Ｆｃ融合タンパク質およびＴＩＭ−３抗原結合ドメインを含む、ＴＩＭ−３標的化ヘテロ二量体融合タンパク質
KR20210003813A (ko) 2018-04-18 2021-01-12 젠코어 인코포레이티드 IL-15/IL-15Rα Fc-융합 단백질 및 LAG-3 항원 결합 도메인을 함유하는 LAG-3 표적화 이종이량체 융합 단백질
CA3097593A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
GB201809341D0 (en) * 2018-06-07 2018-07-25 Ucb Biopharma Sprl Multi-domain proteins with increased native state colloidal stability
EP3802590A2 (en) 2018-06-08 2021-04-14 Argenx BVBA Compositions and methods for treating immune thrombocytopenia
SG11202103192RA (en) 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
CR20210239A (es) 2018-10-12 2021-12-15 Xencor Inc Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas
WO2020114616A1 (en) 2018-12-07 2020-06-11 Tillotts Pharma Ag Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof
CN113438961A (zh) 2018-12-20 2021-09-24 Xencor股份有限公司 含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白
WO2020148207A1 (en) 2019-01-14 2020-07-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies binding to hla-a2
WO2020152290A1 (en) 2019-01-23 2020-07-30 Encefa Cd31 competitors and uses thereof
WO2020180726A1 (en) 2019-03-01 2020-09-10 Xencor, Inc. Heterodimeric antibodies that bind enpp3 and cd3
EP3980063A1 (en) 2019-06-07 2022-04-13 Argenx BVBA Pharmaceutical formulations of fcrn inhibitors suitable for subcutaneous administration
JP7753184B2 (ja) 2019-07-16 2025-10-14 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） Ｃｄ３８に特異性を有する抗体及びその使用
WO2021041715A2 (en) * 2019-08-30 2021-03-04 University Of Kansas Compositions including igg fc mutations and uses thereof
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
US12577324B2 (en) 2019-12-09 2026-03-17 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies having specificity to HER4 and uses thereof
WO2021122733A1 (en) 2019-12-18 2021-06-24 F. Hoffmann-La Roche Ag Bispecific anti-ccl2 antibodies
KR20220148804A (ko) 2020-01-08 2022-11-07 아르젠엑스 비브이 천포창 장애의 치료 방법
KR20230008751A (ko) 2020-05-12 2023-01-16 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 피부 t-세포 림프종 및 tfh 유래된 림프종을 치료하는 신규한 방법
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
CA3192204A1 (en) 2020-08-19 2022-02-24 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
US12161692B2 (en) 2020-11-02 2024-12-10 Attralus, Inc. SAP FC fusion proteins and methods of use
KR20230156079A (ko) 2021-03-09 2023-11-13 젠코어 인코포레이티드 Cd3과 cldn6에 결합하는 이종이량체 항체
US11859012B2 (en) 2021-03-10 2024-01-02 Xencor, Inc. Heterodimeric antibodies that bind CD3 and GPC3
EP4347647A1 (en) 2021-06-01 2024-04-10 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of b cell depleting agents for the treatment of rheumatic heart disease
WO2022263501A1 (en) 2021-06-18 2022-12-22 F. Hoffmann-La Roche Ag Bispecific anti-ccl2 antibodies
KR102835109B1 (ko) * 2021-10-18 2025-07-18 고려대학교 산학협력단 pH-의존 FcRn 결합력과 FcγRⅡa 결합력이 향상된 인간 IgG1 Fc 변이체들
KR102821393B1 (ko) * 2021-10-18 2025-06-18 고려대학교 산학협력단 pH-의존 FcRn 결합력과 FcγRⅢa 결합 선택성이 향상된 Fc 변이체들
CA3258004A1 (en) 2022-06-15 2023-12-21 argenx BV FCRN/HSA BONDING MOLECULES AND METHODS OF USE
EP4549455A1 (en) * 2022-08-02 2025-05-07 Panolos Bioscience, Inc. Modified fusion protein and use thereof
JP2025531832A (ja) 2022-09-08 2025-09-25 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ＬＴＢＰ２（潜在的形質転換増殖因子β結合タンパク質２）に対する特異性を有する抗体及びその使用
WO2024061930A1 (en) 2022-09-22 2024-03-28 Institut National de la Santé et de la Recherche Médicale New method to treat and diagnose peripheral t-cell lymphoma (ptcl)
WO2024170543A1 (en) 2023-02-14 2024-08-22 Institut National de la Santé et de la Recherche Médicale Anti-cd44 antibodies and uses thereof
WO2024236156A1 (en) 2023-05-17 2024-11-21 Institut National de la Santé et de la Recherche Médicale Anti-cathepsin-d antibodies
WO2025012417A1 (en) 2023-07-13 2025-01-16 Institut National de la Santé et de la Recherche Médicale Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof
KR20250037016A (ko) 2023-09-07 2025-03-17 한국전력공사 생물학적 공정을 통한 메탄 생산을 위한 신규 메탄 생산 균주 Methanothermobacter. sp.KEPCO2 및 이를 이용한 메탄 생산 방법
WO2025120015A1 (en) 2023-12-06 2025-06-12 Institut National de la Santé et de la Recherche Médicale Cd5 targeting antibodies with depleting and t or b-cell activation effects
WO2025224297A1 (en) 2024-04-26 2025-10-30 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to tgfbi and uses thereof
WO2025242732A1 (en) 2024-05-21 2025-11-27 Institut National de la Santé et de la Recherche Médicale Pan antibodies against sars-cov-2 spike protein and uses thereof for therapeutical purposes
WO2025257181A1 (en) 2024-06-11 2025-12-18 Institut National de la Santé et de la Recherche Médicale Antibodies targeting trans-active response dna-binding protein-43 (tdp-43)
WO2026039779A1 (en) 2024-08-15 2026-02-19 Yale University Humanized 3e10 antibodies and antigen binding fragments optimized for rad51 binding
WO2026090160A2 (en) 2024-10-22 2026-04-30 Gilead Sciences, Inc. Cd4-targeted il-15 molecules and methods of use
CN120623322B (zh) * 2025-08-14 2025-12-05 成都蓉生药业有限责任公司 一种人IgG Fc变体、基因片段、表达载体、宿主细胞、IgG抗体及人IgG Fc变体制备方法和应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2228904A (en) 1939-05-10 1941-01-14 Bjorkman Hugo Leonard Wrench
US2228908A (en) 1939-07-12 1941-01-14 Blaw Knox Co Ferrous alloy mill roll
US4666884A (en) 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) * 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5033103A (en) 1988-12-09 1991-07-16 The United States Of America As Represented By The Secretary Of The Air Force Model of the lateral inhibition, energy normalization, and noise suppression processes in the retina
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU654811B2 (en) 1990-03-20 1994-11-24 Trustees Of Columbia University In The City Of New York, The Chimeric antibodies with receptor binding ligands in place of their constant region
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5747035A (en) 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1997043316A1 (en) 1996-05-10 1997-11-20 Beth Israel Deaconess Medical Center, Inc. Physiologically active molecules with extended half-lives and methods of using same
CN1204147C (zh) 1998-02-25 2005-06-01 利思进药品公司 提高以抗体为基础的融合蛋白的循环半衰期的方法
IL138608A0 (en) * 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US7183387B1 (en) * 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
KR100940380B1 (ko) * 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
DK2314686T4 (da) 2000-10-06 2023-08-21 Kyowa Kirin Co Ltd Celler, der danner antistofsammensætninger
WO2002030954A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kogyo Co., Ltd. Method of purifying antibody
FR2816319B1 (fr) 2000-11-08 2004-09-03 Millegen Utilisation d'adn polymerase mutagene pour la creation de mutations aleatoires
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン，エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
US7087600B2 (en) 2001-05-31 2006-08-08 Medarex, Inc. Peptidyl prodrugs and linkers and stabilizers useful therefor
EP2385069A3 (en) * 2003-11-12 2012-05-30 Biogen Idec MA Inc. Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
CN101124245A (zh) * 2003-11-12 2008-02-13 比奥根艾迪克Ma公司 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法
EP1706424B1 (en) * 2004-01-12 2009-07-22 Applied Molecular Evolution, Inc. Fc region variants
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
BRPI0517837A (pt) * 2004-11-12 2008-10-21 Xencor Inc variantes fc com ligação alterada a fcrn
FR2879204B1 (fr) 2004-12-15 2007-02-16 Lab Francais Du Fractionnement Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
FR2894983B1 (fr) 2005-12-16 2012-08-17 Lab Francais Du Fractionnement Test de caracterisation des anticorps.
KR100932915B1 (ko) 2007-12-11 2009-12-21 한국전자통신연구원 방사방향 제어장치 및 방법
KR101834999B1 (ko) * 2008-10-14 2018-03-06 제넨테크, 인크. 이뮤노글로불린 변이체 및 그의 용도
US20100113929A1 (en) 2008-10-31 2010-05-06 National Tsing Hua University High-frequency ultrasonic imaging system and method
US10817851B2 (en) 2009-12-23 2020-10-27 Aristocrat Technologies Australia Pty Limited System and method for cashless gaming
US11392902B2 (en) 2017-06-06 2022-07-19 United Parcel Service Of America, Inc. Systems, methods, apparatuses and computer program products for providing notification of items for pickup and delivery

Also Published As

Publication number Publication date
CN104892762A (zh) 2015-09-09
EP4491226A3 (en) 2025-06-11
KR20160105547A (ko) 2016-09-06
PL2805969T3 (pl) 2019-08-30
JP5770710B2 (ja) 2015-08-26
IL215041A0 (en) 2011-11-30
JP2012524522A (ja) 2012-10-18
IL215041A (en) 2016-06-30
EP2805969B1 (en) 2018-12-26
CA2755905A1 (en) 2010-09-23
EP2805969A3 (en) 2016-03-30
CA2995516C (en) 2022-04-26
CA2995516A1 (en) 2010-09-23
EP3395831B1 (en) 2020-03-11
KR101757136B1 (ko) 2017-07-11
EP2805969A2 (en) 2014-11-26
PL2805969T4 (pl) 2019-08-30
TR201904385T4 (tr) 2019-04-22
BRPI1014525A2 (pt) 2016-04-05
CA3069425A1 (en) 2010-09-23
DK2805969T3 (en) 2019-04-15
AU2010224800A1 (en) 2011-10-13
USRE46585E1 (en) 2017-10-24
IL245050A0 (en) 2016-05-31
KR20160145850A (ko) 2016-12-20
EP3674318B1 (en) 2024-11-27
BRPI1014525B1 (pt) 2021-11-23
USRE45992E1 (en) 2016-05-03
CN102405231A (zh) 2012-04-04
KR101781318B1 (ko) 2017-09-22
CA2755905C (en) 2018-05-22
KR20110128883A (ko) 2011-11-30
ES2726625T3 (es) 2019-10-08
BR122021019353B1 (pt) 2022-07-05
DK3674318T3 (da) 2025-02-03
JP5951856B2 (ja) 2016-07-13
US20120009188A1 (en) 2012-01-12
CA3069425C (en) 2022-07-05
EP2408813A2 (en) 2012-01-25
WO2010106180A3 (en) 2010-12-09
AU2010224800B2 (en) 2015-02-05
CN102405231B (zh) 2015-08-19
EP2233500A1 (en) 2010-09-29
WO2010106180A2 (en) 2010-09-23
JP2016014020A (ja) 2016-01-28
KR101797248B1 (ko) 2017-11-14
EP3395831A1 (en) 2018-10-31
US8742074B2 (en) 2014-06-03
EP4491226A2 (en) 2025-01-15
EP3674318A1 (en) 2020-07-01
ES3014619T3 (en) 2025-04-23

Similar Documents

Publication Publication Date Title
FIC20230010I1 (fi) Sasitutsumabigovitekaani
DK3674318T3 (da) Optimerede fc-varianter
NL301265I1 (nl) Quizartinib
HUE045331T2 (hu) Szikkasztótest
DK2430035T3 (da) Uracylspipooxetannukleosider
DE112009005323A5 (de) Hebelarmprüfmaschine
HUE038760T2 (hu) Hulladékhõ-visszanyerõrendszer
BR112012004964A2 (pt) girocóptero
FI20095891A0 (fi) Polttomoottorisovitelma
EP2409976A4 (en) GLYCINE TRANSPORTER INHIBITOR
DE112010003255A5 (de) Fördergutverteiler
EP2454221A4 (en) cineole
FI20095852A0 (fi) Suuntaajalaite
EP2518828A4 (en) Rfid tag
FI20090100A0 (fi) Biotinidaasimääritys
EP2392475A4 (en) NECESSARY TO PAINT
FR2949748B1 (fr) Bouee-balise
FI20090173A0 (fi) Pystypuun karsintalaite
FI20095139A0 (fi) Kaasukasvatusreaktori
NO20091744L (no) Babylogger
FI8456U1 (fi) Pistoansas
FI8446U1 (fi) Pilkekone
FI8712U1 (fi) Patterikannake
FI8384U1 (fi) Polttopuupakkaus
FI8548U1 (fi) Paalutusjärjestelmä